KALA BIO, Inc.
Clinical-stage biopharma developing therapies for rare and severe eye diseases.
KALA | US
Overview
Corporate Details
- ISIN(s):
- US4831192020
- LEI:
- Country:
- United States of America
- Address:
- 1167 MASSACHUSETTS AVENUE, 2476 ARLINGTON
- Website:
- https://www.kalarx.com/
- Sector:
- Manufacturing
Description
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing innovative therapies for rare and severe eye diseases. The company utilizes its proprietary mesenchymal stem cell secretome (MSC-S) platform to create therapies with regenerative healing effects. Its lead product candidate, KPI-012, is a topical therapy in a Phase 2b clinical study for the treatment of persistent corneal epithelial defect (PCED), for which it has received Orphan Drug and Fast Track designations from the U.S. FDA. The pipeline also includes KPI-014, a preclinical, gene-agnostic intravitreal therapy being developed for inherited retinal degenerations. Following the sale of its commercial products in 2022, KALA BIO has concentrated its efforts on advancing its biologics pipeline for ophthalmic conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all KALA BIO, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for KALA BIO, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for KALA BIO, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
